Aims. rombocytopenia complicates the management of patients with chronic liver disease (CLD) undergoing invasive procedures with a bleeding risk. Until recently, prophylactic platelet transfusion was the only treatment option, but has significant safety and efficacy limitations. Phase 3 data demonstrated the superiority of avatrombopag to placebo in reducing platelet transfusions for bleeding, supporting its recent approval. Methods. Integrated analyses of pooled data (푁 = 435) from two randomized, double-blind, placebo-controlled, phase 3 studies assessed the original efficacy endpoints. Additional analyses included subgroup analyses, alternate Baseline platelet count definitions, and another efficacy endpoint. Results. Avatrombopag was superior to placebo in increasing patients not requiring a platelet transfusion or rescue procedure, those achieving a platelet count ≥50 × 10 9 /L on Procedure Day, and the change in platelet counts from Baseline. e avatrombopag treatment effect was consistently positive across clinically important disease and Baseline clinical characteristic subgroups, and using alternate Baseline platelet count cohort definitions. Similarly, more avatrombopag-treated patients achieved ≥50 × 10 9 /L platelets with an increase of ≥20 × 10 9 /L from Baseline. e incidence and severity of adverse events were similar between avatrombopag and placebo. Further, safety data demonstrated a low risk for thromboembolic events and hepatotoxicity. Conclusion. ese integrated analyses confirmed the superiority of avatrombopag to placebo in reducing platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD scheduled to undergo an invasive procedure, and its tolerable safety profile. Importantly, these data warrant reconsideration of clinical decision making regarding the need to treat thrombocytopenia in patients with CLD. is trial was registered with NCT01972529 and NCT01976104.
Introduction
rombocytopenia (platelet count <150 × 10 9 /L) is common in patients with chronic liver disease (CLD), affecting up to 84% of patients with cirrhosis [1, 2] , and worsens with the severity of liver disease; it is associated with increased risks of bleeding, morbidity, and mortality [2] [3] [4] . rombocytopenia complicates the management of patients with CLD, who require multiple, routine, invasive procedures over the course of their disease, many with a bleeding risk [1, 5] . e risk of bleeding varies with degree of thrombocytopenia, the patient's coagulopathy status and type of procedure [2, 4, 6] . e decision to prophylactically treat thrombocytopenia in these patients before an invasive procedure is based on an assessment of the bleeding risk, coagulation abnormalities, the procedure, and clinical guidelines [7] [8] [9] [10] [11] [12] [13] . While several guidelines recommend prophylactic platelet transfusion for platelet counts <50 × 10 procedures [7] [8] [9] [10] [11] [12] [13] . Definitive data on actual bleeding rates with various procedures and platelet counts are lacking, and there remains the inability to a priori predict which patients undergoing which procedures will have bleeding.
Until recently, platelet transfusion was the only prophylactic treatment option for thrombocytopenia in patients with CLD undergoing a procedure, and it has significant limitations including variable and transient efficacy, and the risks of transfusion reactions and infections, which may be fatal [14] . Another important consideration is the potential development of antiplatelet antibodies a er multiple transfusions, which can render these patients refractory to subsequent platelet transfusions [10] . is can negatively impact patient eligibility for liver transplantation, and creates another challenge for managing these patients who have an increased risk of spontaneous bleeding due to gastric and esophageal varices [10] . Further, platelet-transfusion refractoriness o en leads to delayed or cancelled procedures, extends hospitalizations, increases bleeding, and decreases survival [15, 16] . Until recently, the lack of alternatives to platelet transfusions, that eliminate their associated risks, had limited the options for healthcare providers to either transfuse or not transfuse platelets for their patients with CLD-associated thrombocytopenia undergoing procedures. Clinicians had to weigh the risks of using prophylactic platelet transfusions against the uncertain bleeding risks of proceeding with a procedure without treating the thrombocytopenia, and, in the latter case, had to assume some risk of bleeding.
In 2018, avatrombopag (Doptelet®) became the first thrombopoietin (TPO) receptor agonist approved by FDA as an alternative to platelet transfusions for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure [17, 18] ; subsequently, a second TPO receptor agonist, lusutrombopag (Mulpleta®), was also approved [19, 20] . Avatrombopag binds to a different site than endogenous TPO on the TPO receptor, and mimics TPO's biologic effects, resulting in increased platelet counts [18, 21] . Efficacy and safety data for avatrombopag in treating thrombocytopenia in patients with CLD have been reported [22, 23] . e phase 3 trials (ADAPT-1 and ADAPT-2) enrolled 435 patients and represent the largest published dataset for TPO receptor agonists in the CLD patient population. e aim of this integrated analysis of the pooled data for avatrombopag from the phase 3 trials was to provide additional safety and efficacy data to guide healthcare providers and explore additional, post-hoc, alternate efficacy, and subgroup analyses.
Materials and Methods
ADAPT-1 and ADAPT-2 were identically designed, global, randomized, double-blind, placebo-controlled, phase 3 studies using avatrombopag to treat adults with thrombocytopenia associated with CLD. Eligible patients were ≥18 years old with CLD (Model for End-Stage Liver Disease [MELD] score ≤24) and a mean platelet count of <50 × 10 9 /L at Baseline. All patients were to undergo a procedure with a bleeding risk that would require a platelet transfusion unless platelet counts increased from Baseline. Patients were excluded if pregnant; had arterial or venous thrombosis; portal vein blood flow <10 cm/second; World Health Organization (WHO) grade 3 or 4 bleeding; abnormal platelet aggregation; or an active infection requiring antibiotics. All patients provided written informed consent.
Eligible patients were enrolled into 1 of 2 tailored dosing cohorts by their mean platelet count at Baseline, then stratified by procedure bleeding risk (low, moderate, or high) and presence of hepatocellular carcinoma (yes or no). Patients in the Low Baseline Platelet Count Cohort (<40 × 10 9 /L) were randomized 2 : 1 to receive 60 mg avatrombopag or placebo once daily with food on days 1 through 5; patients in the High Baseline Platelet Count Cohort (40 to <50 × 10 9 /L) were randomized 2 : 1 to receive five daily doses of 40 mg avatrombopag or placebo. Doses were selected based on PK/PD modeling to maximize patients achieving platelet counts ≥50 × 10 9 /L, while limiting patients achieving platelet counts >200 × 10 9 /L. Procedure Day was scheduled 5-8 days a er the last dose of the study drug (Days 10-13).
Efficacy endpoints were the same in both phase 3 studies. e primary endpoint was the proportion of patients (Responders) who did not require a platelet transfusion or rescue procedure for bleeding a er randomization, and up to 7 days following a scheduled procedure. Secondary endpoints included the proportion of patients achieving the target platelet count (≥50 × 10 9 /L) on Procedure Day, and the change in platelet count from Baseline to Procedure Day. For the integrated analyses, additional post-hoc, alternate efficacy analyses included: analyses of the primary endpoint by various Baseline platelet count subgroups (10 to <20; 20 to <30; 30 to <40; and 40 to <50) and using alternate Baseline platelet count cohort cutoffs (<35 × 10 /L on Procedure Day and an increase of ≥20 × 10 9 /L from Baseline. e pooled Full Analysis Set (FAS) was used for all efficacy analyses and included all randomized patients. e pooled Per Protocol Analysis Set (PPAS) was used for a sensitivity analysis, and included all randomized patients who received the study drug and did not have major protocol violations (e.g., Baseline platelet count >50 × 10 9 /L, no planned platelet transfusion, transfusion before Procedure Day, prohibited con-medications, bleeding at Baseline, no conducted procedure, received different dose or <80% of total planned dose). e Safety Analysis Set (SAS) consisted of patients who received ≥1 dose of the study drug and had ≥1 post-dose safety assessment. /L (14.9%) or portal vein blood flow was <10 cm/second (3.6%). e disposition of randomized patients was similar between treatment groups in both Baseline platelet count cohorts (Figure 1 ). Only 1 avatrombopag patient Similarly, the increase in platelet counts from Baseline to Procedure Day, the second (secondary endpoint) was higher for avatrombopag-compared to placebo-treated patients in both Baseline platelet count cohorts, with statistically significant treatment differences (Low Baseline Platelet Count Cohort: Δ26.5 × 10 9 /L, 푃 < 0.0001; High Baseline Platelet Count Cohort: Δ34.5 × 10 9 /L, 푃 < 0.0001 (Table 1) ) for both Baseline platelet count cohorts, mean platelet counts in avatrombopag-treated patients approximately doubled from Baseline values.
Results

Patients Demographics and Baseline
Primary Efficacy Endpoint Subgroup Analyses.
A consistently positive avatrombopag treatment effect for the primary endpoint was confirmed across subgroups, including Baseline platelet count, age, gender, race, geographic region, bleeding risk, MELD Score, CTP Grade, and liver disease etiology ( Figure 2 ). e treatment differences were generally similar favoring avatrombopag and were consistent with the results of the overall FAS analysis; subgroups with the smallest number of patients had the widest confidence intervals. e investigators also identified 110 patients with splenomegaly and 325 patients without. Efficacy endpoints did not differ amongst the 2 populations (data not shown).
Exploratory Analyses.
In the post-hoc integrated analysis of the primary efficacy endpoint, the proportion of Responders was consistently higher for avatrombopag-treated patients across various Baseline platelet count subgroups (20 to <30, 30 to <40, and 40 to <50 × 10 9 /L), although the difference in the 10 to <20 × 10 9 /L subgroup (푛 = 15) was small ( Figure   ( anemia and myalgia) and 1 placebo patient (acute myocardial infarction) were discontinued due to treatment-emergent adverse events (TEAEs). Study drug exposure was comparable across treatment groups in both the Low and High Baseline Platelet Count Cohorts, with nearly all patients receiving 5 days of treatment (avatrombopag-96.8%; placebo-97.5%).
Efficacy Endpoints.
In the integrated analysis of the pooled phase 3 data, avatrombopag was superior to placebo in both Baseline platelet count cohorts in reducing platelet transfusions or rescue procedures, with more Responders to the avatrombopag compared to placebo treatment groups in both the Low and High Baseline Platelet Count Cohorts with treatment differences that were clinically meaningful and highly statistically significant (Δ38.3%, 푃 < 0.0001; and Δ52.2%, 푃 < 0.0001, respectively) ( Table 1) . Nearly all (93.8%) Responders in the avatrombopag treatment group had platelet counts ≥50 × 10 9 /L on Procedure Day, compared to only 38.0% of placebo-treated patients who were "Responders. "
For both Baseline platelet count cohorts, more avatrombopag-treated patients in the pooled FAS achieved the secondary endpoint, achieving a platelet count of ≥50 × 10 9 /L on Procedure Day, compared to placebo, with clinically meaningful and statistically significant treatment differences (Low Baseline Platelet Count Cohort: Δ62.6%, 푃 < 0.0001; High Baseline Platelet Count Cohort: Δ60.7%, 푃 < 0.0001 (Table 1) ). Importantly, the tailored dosing strategy based on Baseline platelet counts also limited the number of avatrombopag-treated patients achieving platelet counts >200 × 10 9 /L to 3/277 (1.1%). Last-observation-carried-forward is used for subjects with missing platelet count on the Procedure Day.
* /L (Figure 3(c) ). In the primary endpoint analyses using the alternate Baseline platelet count cohort definition (<35 × 10 (Figure 4(a) ).
3(a)). Overall, there was generally a doubling of platelet counts observed with avatrombopag from Baseline. More patients treated with avatrombopag achieved the secondary endpoint, a platelet count ≥50 × 10 9 /L on Procedure Day, in the 20 to <30, 30 to <40, and 40 to <50 × 10 9 /L Baseline platelet count subgroups compared to placebo (Figure 3(b) ). Similarly, across all Baseline platelet count subgroups, the mean change in platelet count from Baseline to Procedure Day was considerably higher in the avatrombopag treatment TEAE of partial portal vein thrombosis, and 2 placebo-treated patients had thromboembolic events (acute myocardial infarction; disseminated intravascular coagulation/pulmonary embolus).
Discussion
e pooled data from the two, identically designed phase 3 studies of avatrombopag in patients with thrombocytopenia and CLD undergoing scheduled procedures, ADAPT-1 and ADAPT-2, provide a robust database (푁 = 435) to further assess the safety and efficacy of avatrombopag, and enabled the evaluation of additional, important post-hoc, alternate efficacy and subgroup analyses to further guide healthcare providers. As previously reported [22, 23] , patient demographics and Baseline characteristics were generally well balanced across treatment groups in each study.
Primary endpoint analysis of the pooled ADAPT-1 and ADAPT-2 data confirmed the superiority of avatrombopag to placebo in both Baseline platelet count cohorts, with a higher proportion of avatrombopag-treated patients not requiring a platelet transfusion or rescue procedure for bleeding. e treatment differences were both clinically meaningful and statistically significant (푃 < 0.0001).
Avatrombopag was also superior to placebo using the alternate secondary efficacy endpoint definition, the proportion of patients with platelet counts ≥50 × 10 9 /L on Procedure Day and an increase of ≥20 × 10 9 /L from Baseline (Low Baseline Platelet Count Cohort: Δ60.9%, 푃 < 0.0001; High Baseline Platelet Count Cohort: Δ67.5%, 푃 < 0.0001) (Figure 4(b) ).
Safety Analyses.
e pooled SAS included 430 patients. e overall incidence of TEAEs was comparable between the avatrombopag and placebo treatment groups (Low Baseline Platelet Count Cohort: avatrombopag-56.0%; placebo-58.2%; High Baseline Platelet Count Cohort: avatrombopag-51.3%; placebo-50.8%), with most events being mild to moderate (Table 2) ; the most common TEAEs in both treatment groups included pyrexia, abdominal pain, nausea, and headache.
e incidence of treatment-related TEAEs was lower in the combined avatrombopag treatment group (9.5%) compared to placebo-treated patients (12.8%). e incidence of CTCAE Grade 3 TEAEs was similar in the avatrombopag (10.9%) and placebo (10.3%) treatment groups, as was serious TEAEs (avatrombopag-7.3%; placebo-9.0%); the only serious TEAEs reported in more than an individual avatrombopag-treated patient were gastrointestinal hemorrhage and hyponatremia (2 patients each). One avatrombopag-treated patient had a Efficacy data for another TPO receptor agonist, lusutrombopag, were recently presented using alternate definitions for the Baseline platelet count cohorts and secondary efficacy endpoint [25] . To enable benchmarking, efficacy analyses were conducted with the pooled phase 3 data using these alternate definitions. Again, avatrombopag was superior to placebo in both the Alternate Low and Alternate High Baseline Platelet Count Cohorts, with more Responders in avatrombopag-treated patients (푃 < 0.0001).
e integrated analyses of both predefined secondary efficacy endpoints using the pooled phase 3 data were consistent with the primary endpoint data, again demonstrating the superiority of avatrombopag over placebo in this patient population. e significantly higher proportion of avatrombopag-treated patients achieving a platelet count of ≥50 × 10 9 /L in both Baseline platelet count cohorts (푃 < 0.0001) is an important clinical endpoint that helps guide clinical decision making regarding the use of avatrombopag. Similarly, there was a significant treatment difference between avatrombopag-and placebo-treated patients for the alternate secondary efficacy endpoint, i.e., the proportion of patients with a platelet count ≥50 × 10 9 /L and an increase of ≥20 × 10 9 /L from Baseline (푃 < 0.0001). Further, the integrated analyses also confirmed the superiority of avatrombopag to placebo for the second, predefined, secondary efficacy endpoint (푃 < 0.0001), demonstrating a larger change in platelet count from Baseline, with an approximately doubling of Baseline platelet counts in avatrombopag-treated patients in both Baseline platelet count cohorts.
Avatrombopag was also shown to be well tolerated in the integrated safety analyses. ese safety data support a profile Importantly, integrated analyses of the pooled phase 3 data enabled a more robust evaluation of efficacy in various predefined, clinically relevant patient subgroups. e analyses by major demographic factors and relevant intrinsic and extrinsic factors were generally consistent with the overall results in the pooled efficacy analyses of the phase 3 studies. e proportion of Responders in all evaluated subgroups favored avatrombopag, supporting the consistent efficacy of avatrombopag across age, gender, race, region, and procedure bleeding risk. Similarly, efficacy was consistent across key Baseline disease variables, including MELD Score, CTP Grade, and Liver Disease Etiology.
Importantly, the integrated analyses confirmed the rationale for defining tailored dosing based on the platelet count at Baseline, recognizing that patients with lower platelet counts needed a larger increase to reach the target (≥50 × 10 9 /L), and therefore required a higher avatrombopag dose (60 mg). Further from a safety perspective, tailored dosing minimized the number of avatrombopag-treated patients achieving platelet counts >200 × 10 9 /L (1.1%); such high platelet counts have been associated with an increased risk of PVTs with another TPO receptor agonist (eltrombopag) in the same patient population [24] . A further post-hoc analysis of various Baseline platelet count subgroups using the pooled study data showed a consistently higher proportion Responders in avatrombopag-treated patients with counts 20 to <30, 30 to <40, and 40 to <50 × 10 9 /L. While a smaller treatment difference was noted in the smallest Baseline platelet count subgroup (10 to <20 × 10 9 /L; 푛 = 15), it remains to be evaluated whether this subgroup would have benefited from a higher dose of avatrombopag. safety and efficacy data for avatrombopag from this integrated analysis of the pooled phase 3 data support a change in the benefit-risk assessment and clinical decision making favoring the use of avatrombopag, and have the potential to change the standard of care for managing thrombocytopenia in these patients with CLD undergoing a scheduled procedure.
Data Availability e data supporting these integrated and subgroup analyses are from previously reported studies, which have been cited.
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for avatrombopag that was generally comparable to placebo, with the frequency, severity, and types of AEs reported being consistent with those expected in patients with CLD, and no new or unexpected safety signals. ere were no safety data to suggest dose-related toxicities, hepatotoxicity, an increased incidence of thromboembolic or bleeding events in avatrombopag-treated subjects, and no rebound thrombocytopenia with discontinuation. Importantly, the recommended dosing regimen of avatrombopag led to a lesser risk for higher platelet counts (≥200 × 10 9 /L) which subsequently translated to a lower risk of thromboembolic events. ese data support the use of avatrombopag as a safe alternative treatment option for thrombocytopenia in patients with CLD, and with its recent FDA approval, importantly impact the benefit-risk assessment for the treatment of these patients undergoing scheduled procedures.
Clinical decision making regarding the need to treat thrombocytopenia in patients with CLD remains limited by the lack of definitive data defining the actual risk of bleeding for this patient population, which is further confounded by the variable balance of procoagulant and anticoagulant factors in individual patients, and the differing bleeding risks of specific invasive procedures. For the healthcare provider who has made the decision to treat thrombocytopenia in a specific patient with CLD in advance of an invasive procedure, these safety and efficacy data warrant a reassessment of the benefit-risk profile for using a platelet transfusion versus this new treatment option. Given that avatrombopag is an oral agent that stimulates patients' own megakaryocytes to produce platelets, it eliminates the risks of transfusion reactions or infections, and avoids the development of platelet refractoriness; this importantly preserves the option to utilize platelet transfusions emergently for spontaneous bleeding for which these patients are already at increased risk.
In the absence of compelling data on bleeding risk and globally accepted clinical guidelines for treating these patients undergoing invasive procedures, there remains uncertainty regarding the need to prophylactically treat thrombocytopenia in some cases. e limited utility of routine laboratory-based coagulation tests and their questionable relevance to actual thrombotic and bleeding risks is well established in patients with CLD, and rarely is a comprehensive assessment of individual coagulation factors conducted. Clinicians have been handicapped, having no a priori way to predict which patients is undergoing which procedure will continue to have a bleeding complication. Clinical decision making prior to the availability of avatrombopag involved the benefit-risk assessment of platelet transfusion versus no transfusion for the management of thrombocytopenia in patients with CLD undergoing a scheduled procedure. e known risks associated with platelet transfusions and uncertain risks particularly for "low bleeding risk procedures" supported the decision to not transfuse platelets in many cases, accepting that there remained some bleeding risk in doing the procedure without a platelet transfusion. However, with the recent approval of avatrombopag for the treatment of thrombocytopenia in patients with CLD undergoing a scheduled procedure, there are now 3 treatment options to consider: (1) transfuse platelets, (2) not transfuse platelets, or (3) treat with the TPO receptor agonist avatrombopag. e
